Abstract
AbstractImmune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation during their use is increasingly recognized and reported. Herein, we present a 58-year-old lady with advanced non-small cell lung cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 immune histochemistry (IHC) strongly positive in 95% of tumor cells, on ongoing treatment with Pembrolizumab as a first-line monotherapy. Our patient presented with 1-week history of productive cough and high-grade fever. Further workup yielded the diagnosis of pulmonary tuberculosis after her Pembrolizumab sixth cycle with positive AFB smear and TB PCR from BAL (rifampin resistance not detected), with negative HIV status. Hence, immunotherapy was held, and patient was commenced on anti-TB regimen. History revealed contact with active TB patient over the past decade, without previous documentation of latent TB or previous TB infection. Her sputum AFB smear remained persistently positive 4 weeks through anti-TB regimen course. Later, the patient was discharged after her sputum was cleared from AFB (two negative sets). In light of pembrolizumab mechanism of action as an immune checkpoint inhibitor, we suspected its implication on reactivating latent TB which was observed in our patient demonstrating features of pulmonary tuberculosis. She was not re-challenged with Pembrolizumab following TB diagnosis.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference35 articles.
1. Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp mol med 50(12):1–11
2. Cancer Institute N (2015) Definition of immune checkpoint inhibitor—NCI Dictionary of Cancer Terms—National Cancer Institute [cited 2020 Feb 14] Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor. Accessed 14 Feb 2020
3. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. https://doi.org/10.3389/fphar.2017.00561
4. Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18(24):6580–6587. [cited 2020 Feb 15] Available from: https://www.ncbi.nlm.nih.gov/pubmed/23087408. Accessed 15 Feb 2020
5. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2020) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8: 239–45 [cited 2020 Feb 14] Available from: https://www.ncbi.nlm.nih.gov/pubmed/17304234. Accessed 15 Feb 2020
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献